NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

<div>NPT1220-312 blocks TLR2-mediated secretion of inflammasome markers. The NLRP3 inflammasome in THP1 cells differentiated to macrophages was primed with 1.5 ng/ml of Pam3CSK4 and then activated with 100 μg/ml monosodium urate (MSU): (a) NPT1220-312 but not MCC950 blocked Pam3CSK4-evoked release of SEAP. (b) Both MCC950 and NPT1220-312 blocked IL-1β release. (c) Both MCC950 and NPT1220-312 blocked IL-18 release. (d) NPT1220-312 but not MCC950 blocked Pam3CSK4-evoked release of ASC.</div>

International Journal of Inflammation

fig5

Figure 5

Figure 5: NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation 

Figure 5 | NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation 